Watch Again “Advanced Strategias on Bifurcations Management” in our Youtube Account Program Provisional stent technique as a treatment philosophy: the step by step and when to use it. Critical analysis of the POT, Kissing, Re POT technique. Provisional strategy vs 2 stents in No ULM The case in which I require a second stent: when,<a href="https://solaci.org/en/2021/10/05/watch-again-advanced-strategias-on-bifurcations-management-in-our-youtube-account/" title="Read more" >...</a>
01- ESC 2021 | Updated European Society of Cardiology Guidelines for the Management of Valvular Heart Disease Early intervention in asymptomatic valvular heart disease, age recommendations to decide between TAVR and surgery for aortic stenosis, and a push in favor of transcatheter repair in secondary mitral regurgitation are some of the new modifications to the European<a href="https://solaci.org/en/2021/10/01/the-most-read-scientific-papers-of-september-in-interventional-cardiology/" title="Read more" >...</a>
In patients at high risk of bleeding undergoing coronary stenting with a Xience stent, 1-to-3-month DAPT period resulted non-inferior to a 6-to-12-month period in terms of ischemic events, and this could be associated to a lower rate of major bleeding and lower stent thrombosis incidence. There is no longer an indication for conventional stents in<a href="https://solaci.org/en/2021/09/27/xience-short-dapt-ideal-dapt-period-for-patients-at-high-risk-of-bleeding/" title="Read more" >...</a>
✔️ MEDTRONIC Symposium in the SOLACI-CACI 2021 Virtual Congress.✔️ Topic: Current Controversies in Interventional Cardiology. 👨‍🏫 Program: Opening – Dr. Aníbal Damonte. Controversy in Bifurcation Lesions: Which Strategy is Adequate When Implanting Two Stents Is Possible? DK Crush as an Option – Dr. Carlos Uribe. Provisional Stenting as an Option – Dr. Ricardo Costa<a href="https://solaci.org/en/2021/09/13/solaci-caci-2021-current-controversies-in-interventional-cardiology-medtronic-symposium/" title="Read more" >...</a>
01- Best Revascularization Strategy in Patients with Left Ventricular Deterioration Multivessel disease associated to ventricular function deterioration is challenging in terms of risk, when choosing a revascularization strategy. Read also HERE 02- SOLACI Renewed Authorities During the SOLACI-CACI 2021 Congress After a massive event attended by thousands of people, the Latin American Society of Interventional Cardiology renewed its authorities for<a href="https://solaci.org/en/2021/09/10/the-most-read-articles-in-august-in-interventional-cardiology/" title="Read more" >...</a>
The HOST-EXAM study (which was prospective, randomized, and open-label, with the participation of 37 Korean sites) was specifically designed to determine the role of aspirin as the long-term antiplatelet therapy of choice after angioplasty with current drug-eluting stents. To this end, the study compared aspirin head-to-head with clopidogrel. Over the course of four years, 5438 patients (mean<a href="https://solaci.org/en/2021/09/10/host-exam-the-study-that-challenges-aspirin-as-long-term-antiplatelet-therapy/" title="Read more" >...</a>
Courtesy of Dr. José Álvarez. In patients at high bleeding risk with drug-eluting stents, the duration of dual antiplatelet therapy has been subjected to ongoing review. Guidelines from the European Society of Cardiology (ESC) and the American College of Cardiology (ACC) suggest shortening this treatment to a maximum of three to six months (Class IIb).<a href="https://solaci.org/en/2021/08/31/esc-2021-master-dapt-dual-antiplatelet-therapy-after-coronary-angioplasty-in-patients-at-high-bleeding-risk/" title="Read more" >...</a>
After 2.5 years of non-stop racing, ultrathin-strut drug-eluting stents (DES) reached the finish line before 2nd generation thin-strut DES. The advantage was in terms of clinically justified lesion revascularization, while rates of infarction, stent thrombosis, cardiac death, and all-cause death were similar. After failure at trying to create new generations of DES based on drugs<a href="https://solaci.org/en/2021/08/13/the-long-marathon-of-ultrathin-vs-2nd-generation-thin-strut-des/" title="Read more" >...</a>
The novel technology of drug-eluting stent Supreme was designed to synchronize antiproliferative drug release and leave a base behind to promote healing. Accelerated endothelial healing after antiproliferative drug release may limit the long-term inflammatory response. This multicenter, single-blind study included 1600 patients who were randomized 2:1 to receive drug-eluting stent Supreme vs. a classic permanent-polymer everolimus-eluting<a href="https://solaci.org/en/2021/07/13/novel-des-technology-promises-to-become-the-next-des-generation/" title="Read more" >...</a>
Here is the third Fellow’s Corner clinical case to keep discussing and learning alongside the entire community of hemodynamics fellows in Latin America. In this instance, we will present a case of True Bifurcation Lesion: Which Strategy Should We Use? Content 1- Case Presentation 2- Case Resolution 3- Expert Commentary Authors: Dr. Carlos Fava (ARG)<a href="https://solaci.org/en/2021/07/05/the-fellows-corner-3rd-clinical-case-true-bifurcation-lesion-which-strategy-should-we-use/" title="Read more" >...</a>